Towards ethical drug pricing: the European Orphan Genomic Therapies Fund
Exploring stem cell frontiers: definitions, challenges, and perspectives for regenerative medicine
12 April 2024
Scoping review of the recommendations and guidance for improving the quality of rare disease registries
6 May 2024
Exploring stem cell frontiers: definitions, challenges, and perspectives for regenerative medicine
12 April 2024
Scoping review of the recommendations and guidance for improving the quality of rare disease registries
6 May 2024

Journal: Gene Ther. 2024 Apr 24. doi: 10.1038/s41434-024-00452-2. Epub ahead of print. PMID: 38658672.

Towards ethical drug pricing: the European Orphan Genomic Therapies Fund

Authors: Johanna Risse 1Merlin Krzemien 1Jan Schnalke 1Thomas Heinemann 2

Affiliation:

  1. Institute for Medical Humanities, University Hospital Bonn, Venusberg-Campus 1, D-53127, Bonn, Germany.
  2. Institute for Medical Humanities, University Hospital Bonn, Venusberg-Campus 1, D-53127, Bonn, Germany. heinemann.pthv@gmx.de.

Abstract:

An increasing number of novel genomic therapies are expected to become available for patients with rare or ultra-rare diseases. However, the primary obstacle to equal patient access to these orphan genomic therapies are currently very high prices charged by manufacturers in the context of limited healthcare budgets. Taking into account ethical pricing theories, the paper proposes the implementation of a pricing infrastructure covering all European member states, which has the potential to promote distributive justice while maintaining the attractiveness of genomic therapy development.

Download: https://www.nature.com/articles/s41434-024-00452-2